Provided by Tiger Fintech (Singapore) Pte. Ltd.

Salarius Pharmaceuticals Inc

0.9899
-0.0001-0.01%
Post-market: 0.99000.0001+0.01%18:53 EDT
Volume:152.07K
Turnover:148.11K
Market Cap:2.11M
PE:-0.22
High:1.01
Open:0.9900
Low:0.8900
Close:0.9900
Loading ...

Salarius Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance Amid Delisting Concerns

Reuters
·
17 Jun

Salarius Pharmaceuticals- Co's Relative Valuation Reduced to $2.31 Mln - SEC Filing

THOMSON REUTERS
·
11 Jun

Salarius Pharmaceuticals Inc - Enters Second Amendment to Merger Agreement With Decoy - SEC Filing

THOMSON REUTERS
·
11 Jun

Salarius Pharmaceuticals- Company Legacy Stockholders to Retain 7.6% Post-Merger - SEC Filing

THOMSON REUTERS
·
11 Jun

Salarius Pharmaceuticals Updates Merger Agreement with Decoy Therapeutics Amid Market Changes

Reuters
·
11 Jun

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

GlobeNewswire
·
16 Apr

BRIEF-Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses

Reuters
·
26 Mar

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising in Silico Activity Against Measles and Related Viruses

THOMSON REUTERS
·
26 Mar

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

GlobeNewswire
·
26 Mar

Salarius Pharmaceuticals 2024 EPS $(5.79) vs $(30.74) YoY

Benzinga
·
24 Mar

Press Release: Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Dow Jones
·
24 Mar

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-Initiated Phase 1/2 Clinical Trial Using Seclidemstat With Azacitidine to Treat Hematologic Cancers

THOMSON REUTERS
·
03 Feb

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

GlobeNewswire
·
03 Feb

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Benzinga
·
14 Jan

Top Midday Gainers

MT Newswires Live
·
14 Jan

Salarius Pharma Shares More than Double on Merger Deal With Decoy Therapeutics

MT Newswires Live
·
14 Jan

BRIEF-Salarius Pharmaceuticals And Decoy Therapeutics Announce Definitive Merger Agreement

Reuters
·
13 Jan

Salarius Pharmaceuticals to Merge with Decoy Therapeutics

Dow Jones
·
13 Jan

Salarius Pharmaceuticals Inc - New Board to Include Rick Pierce, Barbara Hibner, and Three Independent Directors

THOMSON REUTERS
·
13 Jan

Salarius Pharmaceuticals Inc - Combined Company to Be Led by Decoy's Co-Founders

THOMSON REUTERS
·
13 Jan